ExodusPoint Capital Management LP Raises Position in Kura Oncology, Inc. (NASDAQ:KURA)

ExodusPoint Capital Management LP boosted its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 440.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 297,234 shares of the company’s stock after purchasing an additional 242,263 shares during the period. ExodusPoint Capital Management LP’s holdings in Kura Oncology were worth $2,589,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KURA. Vanguard Group Inc. lifted its stake in shares of Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock valued at $41,973,000 after acquiring an additional 615,211 shares during the last quarter. Geode Capital Management LLC lifted its position in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares during the last quarter. Franklin Resources Inc. lifted its position in Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after purchasing an additional 23,113 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Kura Oncology by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company’s stock valued at $5,535,000 after purchasing an additional 10,542 shares during the period. Finally, Trexquant Investment LP grew its holdings in shares of Kura Oncology by 867.8% in the fourth quarter. Trexquant Investment LP now owns 566,945 shares of the company’s stock worth $4,938,000 after purchasing an additional 508,362 shares during the last quarter.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

Kura Oncology Trading Down 2.2 %

KURA opened at $5.76 on Tuesday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $23.48. The stock has a market cap of $465.15 million, a PE ratio of -2.44 and a beta of 0.83. The business has a 50 day moving average of $7.64 and a 200-day moving average of $11.34.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Equities research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the subject of several analyst reports. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday. JMP Securities reiterated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.